Search PubMed⌕ Search

Biomedical subjects

M Collier

Publications and source records attributed to M Collier.

At least 19 recordsLinked to original sources
PubMed1998

Acceptable evidence?

Explore the source record for details and available documents.

Evidence-Based Medicine↗
PubMed1997

Cytogenetic effects of 935.2-MHz (GSM) microwaves alone and in combination with mitomycin C.

This paper focuses on the genetic effects of microwaves from mobile communication frequencies (935.2 MHz) alone and in combination with a chemical DNA-damaging agent (mitomycin C). Three cytogenetic endpoints were investigated after in vitro exposure of human whole blood cells. These endpoints were the 'classical' chromosome aberration test, the sister chromatid exchange test and the alkaline comet assay. No direct cytogenetic effect was found. The combined exposure of the cells to the radiofrequency fields followed by their cultivation in the presence of mitomycin C revealed a very weak effect when compared to cells exposed to mitomycin C alone.

Chromosome Aberrations↗
PubMed1997

Intracellular activation of gelatinase A (72-kDa type IV collagenase) by normal fibroblasts.

Normal fibroblasts cultured as monolayers secrete matrix metalloproteinases (MMP), including gelatinase A (72-kDa type IV collagenase) as inactive zymogens. Previously we found that normal fibroblasts cultured in a type I collagen lattice (dermal equivalent) secrete active gelatinase A. Here we show that the activation of progelatinase A occurs within the cell and that the activator copurifies with Golgi membranes. Cell extracts of fibroblasts cultured in collagen lattices contain active 62-kDa gelatinase A at least 4-6 h before active enzyme is detected in the culture medium. Pulse-chase experiments confirm these results. The activator is membrane-bound and localizes to the Golgi-enriched fraction. Highly purified plasma membranes from lattice cultures are unable to convert gelatinase A from the zymogen to its active form. The activator may be a metalloproteinase because EDTA prevents activation of exogenous proenzyme by membrane fractions. Membrane-type MMP1, the enzyme thought to be responsible for activation of gelatinase A on the plasma membrane of tumor cells, shows no significant change in either mRNA or protein levels during lattice culture. Intracellular levels of gelatinase A mRNA and protein increase during the culture period, and tissue inhibitor of metalloproteinases concentration does not change. Because of the greater availability of tissue inhibitor of metalloproteinases-free proenzyme as a substrate for the activator, it is possible that membrane-type MMP1 is the activating enzyme. In that case, malignant transformation may involve a change in the localization of the activator to the plasma membrane.

Biomarkers↗
PubMed1997

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder.

UNLABELLED: Oral piritrexim (PTX), a second generation antimetabolite, has been shown to be an active agent against methotrexate refractory transitional cell cancer (TCC) of the bladder in phase I trials. We conducted a phase II trial of this drug in patients with TCC of the bladder who failed a first line chemotherapy regimen. METHODS: Oral PTX was started at the dose of 25 mg three times per day for 5 days weekly for 3 weeks followed by one week of rest. If this was tolerated the dose was increased to 50 mg three times a day. Patients were monitored for response rate and toxicity. RESULTS: Seventeen patients were entered into the trial. Two patients did not complete the required 2 courses of treatment to be evaluable. There were 13 evaluable patients. Among the 13 no one achieved a complete response (CR), however, there were 3 partial responses (PRs = RR: 23%) and 5 stable diseases (SDs). The responses lasted 2, 8 and 14 months. The major dose-limiting toxicity was myelosuppression. Two patients died on treatment. One death was due to neutropenic fever and the cause of death in the second patient is thought to be a cerebral vascular accident (CVA). CONCLUSION: PTX is an active drug in the treatment of TCC of the bladder. Bone marrow suppression is the most common dose-limiting toxicity. In view of the observed responses and toxicities in this study and other studies, we suggest that the role of PTX be further investigated in the following clinical settings: 1. Palliative initial treatment in patients with TCC of the bladder who are not candidates for more aggressive chemotherapy. 2. As first line chemotherapy in combination with other active drugs.

Administration, Oral↗
PubMed1996

954 MHz microwaves enhance the mutagenic properties of mitomycin C.

This paper focuses on the combined effects of microwaves from mobile communication frequencies and a chemical DNA damaging agent mitomycin C (MMC). The investigation was performed in vitro by exposing whole blood samples to a 954 MHz emitting antenna from a GSM (Global System for Mobile Communication) base station, followed by lymphocyte cultivation in the presence of MMC. A highly reproducible synergistic effect was observed as based on the frequencies of sister chromatid exchanges in metaphase figures.

Cell Cycle↗
PubMed1994

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.

Renal cell carcinoma exhibits chemoresistance attributable in part to the P-glycoprotein drug efflux mechanism. Acrivastine is a hydrophylic antihistamine that has been shown in vitro to reverse this form of resistance. After five patients were treated on a dose-finding study, seventeen patients with metastatic or unresectable renal cell carcinoma were entered into a phase II study of vinblastine in combination with acrivastine. Patients received oral acrivastine at doses of 400 mg every 4 hours for 6 days and a 96-hour continuous infusion of vinblastine at a dose of 1.6 mg/m2/24 h. Of 15 evaluable patients, no tumor responses were seen. The regimen was well-tolerated with the majority of toxicities being gastrointestinal and hematologic. Serum levels of acrivastine, its principal metabolite (270C81) and vinblastine were measured during the study. Based on in vitro data, the plasma levels of acrivastine were within a range adequate to block P-glycoprotein activity. High doses of acrivastine were well-tolerated clinically, however, the combination of acrivastine and vinblastine was not active against renal cell carcinoma.

Adult↗
PubMed1991

Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies.

A phase I trial of piritrexim was conducted by use of a prolonged, low-dose oral schedule. A number of different regimens were tested, including daily dosing for 21 days followed by 7 days of no drug therapy; continuous dosing; and daily dosing for 5 of 7 days for 3 consecutive weeks followed by a week of rest. Dose escalation was accomplished by increasing the dosing frequency from once a day to twice a day and then to three times a day and by increasing the number of days of administration. Fifty-one patients with advanced cancer were entered in the study. One hundred twenty-four (96%) of 129 courses were considered assessable. Myelosuppression proved to be the dose-limiting toxic effect. Other toxic effects included stomatitis, nausea and vomiting, anorexia, diarrhea, skin rash, fatigue, and elevation of liver transaminase levels. Antitumor activity was observed in patients with melanoma and bladder cancer, and disease stabilization occurred in those with sarcoma and pheochromocytoma. The recommended dosing schedule for phase II clinical trials is 25 mg three times a day for 5 days for 3 consecutive weeks followed by 1 week of no drug therapy.

Administration, Oral↗
PubMed1991

Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.

A phase II trial of piritrexim (2,4-diamino-6[2,5-dimethoxybenzyl]-5-methyl pyrido-[2,3d] pyrimidine, 301U74; PTX) was conducted for patients with metastatic malignant melanoma using an intermittent, low-dose oral administration schedule. PTX was administered at a starting dose of 25 mg orally three times per day for 5 days weekly for 3 weeks followed by 1 week of rest. Thirty-one patients were entered onto the study. Among 31 patients assessable for response, there were two complete responses (CRs) and five partial responses (PRs) for a response rate (CR plus PR) of 23% (95% confidence limit, 10% to 42%). Five responses occurred in soft tissue lesions, and two responses occurred in lung lesions. The initial dose schedule was well tolerated. The dose-limiting toxicity was myelosuppression. PTX administered in this schedule appears to be active against malignant melanoma. Further clinical trials to confirm these results are underway.

Administration, Oral↗
PubMed1990

Measurement of human embryo-derived platelet-activating factor (PAF) using a quantitative bioassay of platelet aggregation.

A quantitative bioassay was used to measure the concentration of platelet activating factor (PAF) in medium in which human embryos produced by IVF had been cultured and in various other biological fluids. Following extraction and partial purification, 121 of 228 (53%) media samples in which single human embryos were cultured for 24 h had PAF levels greater than found in corresponding control media. This was assigned as embryo-derived PAF and the corresponding embryos termed 'PAF-positive'. Medium from those PAF-positive embryos transferred to patients who achieved an ongoing pregnancy had a mean PAF concentration of 295 +/- 107 nM (mean +/- SEM, n = 55), which was significantly greater (P less than 0.03) than media of PAF-positive embryos transferred to patients who failed to become pregnant (75 +/- 27 nM, n = 66, t-test). The embryos with the faster cleavage rates tended to secrete more PAF (P less than 0.01). Although a greater proportion of culture media derived from embryos transferred to patients who achieved a pregnancy were PAF-positive (66 out of 121, 54.5%) compared with those transferred to patients who failed to achieve a pregnancy (55 out of 121, 45.4%), this was not significant (P greater than 0.05). It was observed that 13% of women who achieved a pregnancy had embryos transferred which did not produce significant amounts of PAF in vitro. This occurred in 26% of women not achieving pregnancy.(ABSTRACT TRUNCATED AT 250 WORDS)

Biological Assay↗
PubMed1990

Comparison of false-positive reactions in direct-binding anti-HIV ELISA using cell lysate or recombinant antigens.

In a 2-year study of false-positive anti-HIV-1 tests in blood donors at Manchester and Lancaster Blood Banks, the reactions associated with a HIV-infected cell lysate antigen were compared with those using recombinant-antigen-based tests. In year 1 (cell lysate test) at Manchester BTS 0.21% of 119.178 donations were repeatedly reactive, compared with 0.53% of 119,004 donations in year 2 (recombinant antigen). Reactive sera were tested at Manchester PHL by three different immunoassays. Referred specimens were classified as anti-HIV positive (95-100% reactive in all the assays), equivocal or negative (negative results in all three immunoassays). Two donors were confirmed to be anti-HIV positive over the 2-year period. Most sera were negative by confirmatory immunoassays in years 1 and 2. In year 1, a study of 60 referred sera with sex- and age-matched controls showed high correlation between a reactive anti-HIV-1 screening test and indeterminate anti-HIV-1 patterns on Western blot showing reactions with HIV gag-coded proteins. In year 2, less than 10% of referred sera were reactive by Western blot, and there was no correlation between a reactive screening anti-HIV test, the strength of signal in the test or a reactive Western blot. Follow-up showed that donors whose sera were reactive in years 1 and 2 by the anti-HIV-1 screening test formed almost two different populations. Four donors with equivocal anti-HIV-1 confirmatory tests had anti-HIV 'envelope' reactions.(ABSTRACT TRUNCATED AT 250 WORDS)

Blotting, Western↗
PubMed1990

A sore point.

Explore the source record for details and available documents.

Humans↗